盈利预测

Search documents
How Much Upside is Left in Viant (DSP)? Wall Street Analysts Think 40.12%
ZACKS· 2025-05-20 15:01
Viant Technology (DSP) closed the last trading session at $15.08, gaining 25.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $21.13 indicates a 40.1% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $2.80. While the lowest estimate of $18 indicates a 19.4% increase from the current price level, the most optimistic analyst e ...
Wall Street Analysts Predict a 45.29% Upside in Natural Gas Services (NGS): Here's What You Should Know
ZACKS· 2025-05-20 15:01
Core Viewpoint - Natural Gas Services (NGS) shares have increased by 38% recently, with analysts suggesting a potential upside of 45.3% based on a mean price target of $36.25 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $5.97, indicating variability among analysts [2] - The lowest price target of $32 suggests a 28.3% increase, while the highest target of $45 indicates an 80.4% potential surge [2] - A low standard deviation signifies a high degree of agreement among analysts regarding price movement direction [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about NGS's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - The Zacks Consensus Estimate for the current year has risen by 18.6% over the past month, with no negative revisions [12] - NGS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13]
ESS Tech (GWH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
ZACKS· 2025-05-20 14:56
Core Viewpoint - ESS Tech, Inc. (GWH) has experienced a bearish price trend, losing 14.7% over the past week, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, with selling pressure likely subsiding, which supports a bullish outlook for the stock [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, signaling that bears may be losing control over the price during a downtrend [4][5]. - The occurrence of a hammer pattern at the bottom of a downtrend suggests that bulls may have successfully halted further price declines, indicating a potential trend reversal [5]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for GWH, which is a bullish indicator, as it typically leads to price appreciation in the near term [7]. - Over the last 30 days, the consensus EPS estimate for the current year has increased by 6.8%, indicating that sell-side analysts expect better earnings than previously predicted [8]. - GWH currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which historically outperform the market [9].
零跑汽车:一季度业绩超预期,对2025财年更加乐观-20250520
Zhao Yin Guo Ji· 2025-05-20 01:20
20五月2025 盈利/估值。 我们将2025财年净利润预测从-9800万元上调至11800万元。 我们同样认为,理想汽车在2026财年将实现更显著利润增长。基于近期改善的 市场情绪以及理想汽车盈利前景的提升,我们维持买入评级,并将目标价从50. 00港元上调至72.00港元(基于1.5倍2025财年市销率,此前为1.3倍)。我们 对评级和目标价的主要风险包括销量和/或利润率低于预期,以及行业降级。 收益总结 | (YE 31 Dec) | FY23A | FY24A | FY25E | FY26E | FY27E | | --- | --- | --- | --- | --- | --- | | 收入(人民币百万) | 16,747 | 32,164 | 58,993 | 63,046 | 67,905 | | 同比增长率 (%) | 35.2 | 92.1 | 83.4 | 6.9 | 7.7 | | 毛利率 (%) | 0.5 | 8.4 | 12.1 | 12.9 | 12.8 | | 营业利润(人民币百万元) | (4,377.4) | (3,171.1) | (404.7) | 206.8 | 3 ...
Surging Earnings Estimates Signal Upside for Olo (OLO) Stock
ZACKS· 2025-05-19 17:21
Core Insights - Olo Inc. (OLO) shows potential as a strong investment due to significant revisions in earnings estimates, indicating an improving earnings outlook [1][9] - Analysts are increasingly optimistic about Olo's earnings prospects, which is expected to positively influence its stock price [2][3] - The Zacks Rank system, which rates stocks from 1 (Strong Buy) to 5 (Strong Sell), has a proven track record, with 1 ranked stocks averaging a +25% annual return since 2008 [3][8] Current-Quarter Estimate Revisions - For the current quarter, Olo is projected to earn $0.08 per share, reflecting a +60% increase from the same quarter last year [5] - In the last 30 days, two estimates for Olo have been revised upward while one has been revised downward, leading to a 150% increase in the Zacks Consensus Estimate [5] Current-Year Estimate Revisions - The full-year earnings estimate for Olo is $0.31 per share, representing a +40.91% change from the previous year [6] - Over the past month, one estimate has been revised upward with no negative revisions, resulting in a 92.86% increase in the consensus estimate [7] Favorable Zacks Rank - Olo currently holds a Zacks Rank 2 (Buy) due to positive estimate revisions, which suggests strong potential for stock performance [8] - Research indicates that stocks with Zacks Rank 1 and 2 significantly outperform the S&P 500 [8] Bottom Line - Olo's stock has gained 51.2% over the past four weeks, driven by solid estimate revisions, making it a candidate for portfolio addition [9]
All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy
ZACKS· 2025-05-19 17:06
Core Viewpoint - Edgewise Therapeutics, Inc. (EWTX) has received a Zacks Rank 2 (Buy) upgrade due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is primarily based on a company's changing earnings picture, specifically tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The Zacks rating upgrade for Edgewise Therapeutics reflects a positive outlook on its earnings, which could positively affect its stock price [4][6]. Impact of Earnings Estimates on Stock Prices - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [5]. - Institutional investors utilize earnings estimates to determine the fair value of a company's shares, influencing their buying or selling actions, which subsequently affects stock prices [5]. Recent Performance of Edgewise Therapeutics - Edgewise Therapeutics is projected to earn -$1.82 per share for the fiscal year ending December 2025, indicating a year-over-year decline of 25.5% [9]. - Over the past three months, the Zacks Consensus Estimate for Edgewise Therapeutics has increased by 2.1%, suggesting a positive trend in earnings estimates [9]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of Edgewise Therapeutics to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [11].
Legacy Education Inc. (LGCY) Upgraded to Buy: Here's What You Should Know
ZACKS· 2025-05-19 17:06
Legacy Education Inc. (LGCY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sys ...
Wall Street Analysts Think Rambus (RMBS) Could Surge 28.22%: Read This Before Placing a Bet
ZACKS· 2025-05-19 14:56
Shares of Rambus (RMBS) have gained 23.3% over the past four weeks to close the last trading session at $56.35, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $72.25 indicates a potential upside of 28.2%.The mean estimate comprises eight short-term price targets with a standard deviation of $9.97. While the lowest estimate of $55 indicates a 2.4% decline from the current price ...
Wall Street Analysts See a 34.92% Upside in CI&T (CINT): Can the Stock Really Move This High?
ZACKS· 2025-05-19 14:56
Shares of CI&T Inc. (CINT) have gained 21.5% over the past four weeks to close the last trading session at $6.10, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $8.23 indicates a potential upside of 34.9%.The mean estimate comprises eight short-term price targets with a standard deviation of $1.33. While the lowest estimate of $6.50 indicates a 6.6% increase from the current pr ...
Does West Pharmaceutical (WST) Have the Potential to Rally 31.09% as Wall Street Analysts Expect?
ZACKS· 2025-05-19 14:56
Shares of West Pharmaceutical Services (WST) have gained 7.3% over the past four weeks to close the last trading session at $216.64, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $284 indicates a potential upside of 31.1%.The average comprises 10 short-term price targets ranging from a low of $245 to a high of $355, with a standard deviation of $34.94. While the lowest estimat ...